The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Even light-intensity activities such as walking can reduce one’s risk for clinical depression. So, what are the most common ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Blue Monday originated from a publicity stunt, but seasonal affective disorder is a real affliction that affects millions of ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...